SNGX
SNGX clinical trials: SOLIGENIX, INC.
Every trial on ClinicalTrials.gov where SOLIGENIX, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 12
- Trials linked
- 11
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
SNGX on the catalyst calendar · SNGX registry changes
- Primary completion Oct 22, 2025ActualPhase 2NCT05442190Topical SGX302 for Mild-to-Moderate PsoriasisSoligenix · PsoriasisCompletedSNGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 23, 2025ActualPhase 2NCT06386744Dusquetide for the Treatment of Behcet's DiseaseSoligenix · Behçet DiseaseCompletedSNGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 22, 2026ActualPhase 3NCT06470451Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCLSoligenix · CTCL/ Mycosis FungoidesTerminatedSNGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2024ActualPhase 2NCT06149247HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCLSoligenix · Cutaneous T-Cell Lymphoma/Mycosis FungoidesCompletedSNGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 16, 2022ActualPhase 2NCT05380635PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell LymphomaSoligenix · Cutaneous T-Cell Lymphoma/Mycosis FungoidesCompletedSNGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 24, 2020ActualPhase 3NCT03237325DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck CancerSoligenix · Squamous Cell Carcinoma of the Oral Cavity and OropharynxCompletedSNGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2020ActualPhase 3NCT02448381FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of...Soligenix · Cutaneous T-Cell LymphomaCompletedSNGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2015ActualPhase 2NCT01925950Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)Soligenix · Chronic Gastrointestinal Graft vs Host DiseaseTerminatedSNGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 2NCT02013050A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck CancerSoligenix · Oral MucositisCompletedSNGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2011ActualPhase 3NCT00926575Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)Soligenix · Acute Gastrointestinal Graft vs Host DiseaseTerminatedSNGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2012ActualPhase 1/Phase 2NCT01073384A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal CancerSoligenix · EnteritisCompletedSNGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 22, 2025ActualPhase 2NCT05872854Treatment of Mycosis Fungoides With Hypericin Ointment and Visible LightEllen Kim, MD · Cutaneous T Cell LymphomaCompletedSNGXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner